Love Pharma Inc. (CSE: LUV), an international sexual health, wellness, and psychedelics company, has. Mr. Maurice brings 20 years of experience in consumer goods with a focus on the development of over-the-counter drug and nutraceuticals, including efficacy, clinical research, branding, marketing, advertising, and global retail distribution.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news. If this link is not enabled, please visit and enter "Love Pharma" in the search box.

He was most recently at Callitas Therapeutics where over 4 years he quickly rose through the ranks from Director of Sales & Marketing to VP of Sales & Business Development and then to President. Having successfully launched a number of retail brands from concept to distribution, both direct-to-consumer and with brick-and-mortar retailers including Walmart, CVS, Target, and Walgreens, Mr. Maurice's track record in streamlining manufacturing and supply chain management, while maximizing profitability and product performance should prove invaluable to Love Pharma.

Joshua Maurice, COO, stated: "While I am truly impressed by the breadth of the Love Pharma portfolio-ranging from CBD and psychedelics to sexual wellness and conception-it's being ideally positioned to bring novel health and wellness products to market that really excites me about joining the Love Pharma team; and I look forward to focusing on how our innovative technologies can legitimately improve the lives of our customers."

In his new role at Love Pharma, Mr. Maurice will be responsible for the following:

  • Overseeing day-to-day operations, including logistics and supply chain systems
  • Directing the acquisition of new technologies as well as product development
  • Steering the launch of new products, including key branded products such as BLOOM™ and AURALIEF™, and their respective marketing and advertising campaigns
  • Leading contract negotiations and vendor acquisitions

Zachary Stadnyk, CEO, added: "Joshua's expertise is exactly what we need to properly execute the rollout of new products as well as to oversee the distribution and marketing of our strong portfolio of therapeutic and pharmaceutical products. We welcome Joshua, a talented senior executive with years of experience, to the Love Pharma team, where his guidance and history will make him an invaluable asset; and we look forward to the future growth and expansion that he will lead."

Founded in 2020, Love Pharma is focused on the Global Sexual Health, Wellness, and Psychedelics markets, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

The company is initially launching Bloom, a topical gel that increases blood circulation and sensitivity, with future hemp-infused versions, designed to further improve blood circulation and sensitivity, along with Auralief, a discreet cannabis-infused oral strip that expedites and enhances the desired effects of THC and CBD. The company has a number of other proven products in the pipeline to aid in mental and sexual health and wellness. The company is also actively seeking additional mergers and acquisitions to complement its strong portfolio of intellectual property.

The shares which began trading on the CSE on September 30, are trading at $0.08. For more information, please visit the company's website, contact Zach Stadnyk, President and CEO, at 604-343-2977 or by email at

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

InvestmentPitch Media
Barry Morgan, CFO

To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia

Pfizer Declares Fourth-Quarter 2022 Dividend

Board of Directors approves quarterly cash dividend of $0.40 per share

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 fourth-quarter 2022 dividend on the company's common stock, payable December 5, 2022, to holders of the Common Stock of record at the close of business on November 4, 2022. The fourth-quarter 2022 cash dividend will be the 336th consecutive quarterly dividend paid by Pfizer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Merck Animal Health to Acquire Vence

Virtual fencing system provides advanced technology to cattle producers and ranchers to manage natural resources more effectively

Complements Merck Animal Health's broad portfolio of veterinary pharmaceuticals, vaccines and animal intelligence solutions

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer to Supply Global Fund Up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries

  • Treatment courses will be available for procurement by 132 Global Fund-eligible low-and-middle-income countries in all regions of the world beginning in 2022, subject to local regulatory approval or authorization
  • The agreement is part of Pfizer's comprehensive strategy to work toward worldwide equitable access to COVID-19 oral treatments

Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of health systems strengthening. PAXLOVID treatment courses will be available for procurement through this mechanism, subject to local regulatory approval or authorization, by the 132 grant-eligible countries determined by Global Fund based on income classification and disease burden.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

LYNPARZA® Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient -Positive Advanced Ovarian Cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved in China as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2022. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2022 Performance Report, to be issued that morning.

To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to register in advance of the conference call.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences' lenacapavir to resume with lower dose of islatravir

Monthly oral islatravir development for pre-exposure prophylaxis (PrEP) to be discontinued; Merck continues to evaluate other long-acting PrEP candidates

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News